Epoxomicin
| Names | |
|---|---|
| IUPAC name
(2S,3S)-N-((2S,3R)-3-hydroxy-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxobutan-2-yl)-3-methyl-2-((2S,3S)-3-methyl-2-(N-methylacetamido)pentanamido)pentanamide | |
| Other names
BU 4061T | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C28H50N4O7 | |
| Molar mass | 554.729 g·mol−1 |
| Appearance | White solid |
| Solubility in DMSO | 10 mg/mL |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
Epoxomicin is a naturally occurring selective proteasome inhibitor with anti-inflammatory activity. It was originally discovered in 1992. Injected, it can induce Parkinson's-like symptoms in rats.
Derivatives of epoxomicin include carfilzomib.